KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Terminated · Phase 2 · NCT03919799
Conditions: System, Sclerosis, Diffuse Cutaneous Systemic Sclerosis
At a glance
- Research payments reported, 2025
- $2,715
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 36
About the trial
- Sponsor
- Kadmon, a Sanofi Company
- Tested
- Belumosudil (KD025) (drug), Placebo (drug)
- Dates
- Started 2019-06-26; completion 2023-02-17
- Results posted
- Yes
This randomized, placebo-controlled phase 2 study was seeking to evaluate the efficacy and safety of belumosudil (KD025) for the treatment of diffuse cutaneous systematic sclerosis. Enrolment was terminated earlier than planned for business reasons unrelated to safety. A total of 36 participants were enrolled and randomized into 3 groups to either receive orally administered belumosudil (200 milligrams \[mg\] once daily \[QD\] and 200 mg twice daily \[BID\]) or matched placebo in 1:1:1 ratio in the double-blind (DB) period of this study. Study drug dosing was for 52 weeks: double-blinded for the first 28 weeks followed by an open-label extension of 24 weeks. After unblinding, the particip…
From ClinicalTrials.gov, last updated 2023-08-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $2,715 in research payments for this study in 2025 (2 payments).
Products named: Rezurock
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.